Denteric enters Phase I clinical trials



Denteric is pleased to announce that its first subjects have been dosed today in its first in human safety study of GPV381, a therapy designed to treat severe periodontal disease.

The phase 1 study will assess safety and tolerability of the therapy in healthy subjects and is being conducted at Nucleus Networks Phase I Unit in Melbourne.

The randomised, double-blind placebo-controlled study will test 3 ascending doses for safety and tolerability.

The study’s secondary objectives include evaluating immune responses in blood and saliva.

Development of GPV381 commenced in 2019 and aims to treat severe periodontal disease, a condition that affects almost 1 billion adults globally.

Periodontitis is the 6th most infectious disease globally and left untreated, leads to tooth loss, a particular risk in the elderly.

The disease is caused by chronic inflammation of the gums and supporting tissues of teeth in response to bacterial infection.

The therapy is intended to boost immune responses of patients with severe disease.

Anyone interested in further information on the trial are encouraged to read more at ANZCTR  or to reach out to Nucleus Network to find out how to participate.